Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-06-13T03:16:23.389Z Has data issue: false hasContentIssue false
  • English
  • Français

Chemoradiotherapy for primary CNS lymphoma

Published online by Cambridge University Press:  06 July 2006

Antonio M.P. Omuro ,
Joachim Yahalom  and
Lauren E. Abrey
Antonio M.P. Omuro
Affiliation:
Division de Neurologie Mazarin – Groupe Hospitalier Pitie-Salpetriere, Paris, France; Email: antonio.omuro@psl.ap-hop-paris.fr
Joachim Yahalom
Affiliation:
Department of Radiotherapy – Memorial Sloan-Kettering Cancer Center, New York, NY, USA;Email: yahalomj@mskcc.org
Lauren E. Abrey
Affiliation:
Department of Neurology – Memorial Sloan-Kettering Cancer Center, New York, NY, USA;Email: abreyl@mskcc.org
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

primary central nervous system lymphoneNon-hodgkin's lymphsbrain neoplasmchemotherapyradiotherapy
Type
Review Article
Information
Progress in Neurotherapeutics and Neuropsychopharmacology , Volume 2 , Issue 1 , March 2007 , pp. 123 - 136
Copyright
© 2007 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Original article: Chemoradiotherapy for primary CNS lymphoma: An intent-to-treat analysis with complete follow-up. Published in NEUROLOGY 64 (1): 69–74, January 2005.All authors have read and approved this chapter. Informed consent was obtained from all subjects and/or guardians involved in this study. The authors are responsible for the accuracy of the references.

References

References:

Abrey, L.E., Yahalom, J., & DeAngelis, L.M. (2000). Treatment for primary CNS lymphoma: the next step. Journal of Clinical Oncology, 18, 3144–3150.CrossRefGoogle Scholar
Abrey, L.E., Moskowitz, C.H., Mason, W.P., et al. (2003). Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. Journal of Clinical Oncology, 21, 4151–4156.CrossRefGoogle Scholar
Batchelor, T., Carson, K., O'Neill, A., et al. (2003). Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. Journal of Clinical Oncology, 21, 1044–1049.CrossRefGoogle Scholar
Borsi, J.D., & Moe, P.J. (1987). Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer, 60, 3020–3024.3.0.CO;2-0>CrossRefGoogle Scholar
Chamberlain, M.C., & Levin, V.A. (1990). Adjuvant chemotherapy for primary lymphoma of the central nervous system. Archives of Neurology, 47, 1113–1116.CrossRefGoogle Scholar
Chamberlain, M.C., & Levin, V.A. (1992). Primary central nervous system lymphoma: a role for adjuvant chemotherapy. Journal of Neuro-Oncology, 14, 271–275.CrossRefGoogle Scholar
Cheng, T., Forsyth, P., Chaudhry, A., et al. (2003). High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplantation, 31, 679–685.CrossRefGoogle Scholar
Correa, D.D., DeAngelis, L.M., Shi, W., Thaler, H., Glass, A., & Abrey, L.E. (2004). Cognitive functions in survivors of primary central nervous system lymphoma. Neurology, 62, 548–555.CrossRefGoogle Scholar
DeAngelis, L.M., Yahalom, J., Thaler, H.T., & Kher, U. (1992). Combined modality therapy for primary CNS lymphoma. Journal of Clinical Oncology, 10, 635–643.CrossRefGoogle Scholar
DeAngelis, L.M., Seiferheld, W., Schold, S.C., Fisher, B., & Schultz, C.J. (2002). Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation therapy oncology group study 93–10. Journal of Clinical Oncology, 20, 4643–4648.CrossRefGoogle Scholar
Eby, N.L., Grufferman, S., Flannelly, C.M., Schold Jr, S.C., Vogel, F.S., & Burger, P.C. (1988). Increasing incidence of primary brain lymphoma in the US. Cancer, 62, 2461–2465.3.0.CO;2-M>CrossRefGoogle Scholar
Ferreri, A.J., Abrey, L.E., Blay, J.Y., et al. (2003). Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15, 2002. Journal of Clinical Oncology, 21, 2407–2414.CrossRefGoogle Scholar
Gabbai, A.A., Hochberg, F.H., Linggood, R.M., Bashir, R., & Hotleman, K. (1989). High-dose methotrexate for non-aids primary central nervous system lymphoma. Report of 13 cases. Journal of Neurosurgery, 70, 190–194.CrossRefGoogle Scholar
Glass, J., Gruber, M.L., Cher, L., & Hochberg, F.H. (1994). Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. Journal of Neurosurgery, 81, 188–195.CrossRefGoogle Scholar
Herrlinger, U., Schabet, M., Brugger, W., et al. (2002). German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Annals of Neurology, 51, 247–252.CrossRefGoogle Scholar
Herrlinger, U., Kuker, W., Uhl, M., et al. (2005). NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Annals of Neurology, 57, 843–847.CrossRefGoogle Scholar
Hoang-Xuan, K., Taillandier, L., Chinot, O., et al. (2003). Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Journal of Clinical Oncology, 21, 2726–2731.CrossRefGoogle Scholar
Khan, R.B., Shi, W., Thaler, H.T., DeAngelis, L.M., & Abrey, L.E. (2002). Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? Journal of Neuro-Oncology, 58, 175–178.Google Scholar
Lichtman, S.M., Kolitz, J., Budman, D.R., et al. (2001). Treatment of aggressive non-hodgkin's lymphoma in elderly patients with thiotepa, novantrone (mitoxantrone), vincristine, prednisone (TNOP). American Journal of Clinical Oncology, 24, 360–362.CrossRefGoogle Scholar
Olson, J.E., Janney, C.A., Rao, R.D., et al. (2002). The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology and end results analysis. Cancer, 95, 1504–1510.CrossRefGoogle Scholar
Omuro, A.M., Ben-Porat, L.S., Panageas, K.S., et al. (2005a). Delayed neurotoxicity in primary central nervous system lymphoma. Archives of Neurology, 62, 1595–1600.Google Scholar
Omuro, A.M., DeAngelis, L.M., Yahalom, J., & Abrey, L.E. (2005b). Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology, 64, 69–74.Google Scholar
O'Neill, B.P., Wang, C.H., O'Fallon, J.R., et al. (1999). The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: Cognitive function and performance status. North Central Cancer Treatment Group. Journal of Neuro-Oncology, 1, 196–203.Google Scholar
Pels, H., Schmidt-Wolf, I.G.H., Glasmacher, A., et al. (2003). Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. Journal of Clinical Oncology, 21, 4489–4495.CrossRefGoogle Scholar
Poortmans, P.M., Kluin-Nelemans, H.C., Haaxma-Reiche, H., et al. (2003). High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-aids-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group phase II trial 20962. Journal of Clinical Oncology, 21, 4483–4488.CrossRefGoogle Scholar
Sandor, V., Stark-Vancs, V., Pearson, D., et al. (1998). Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. Journal of Clinical Oncology, 16, 3000–3006.CrossRefGoogle Scholar
Sarazin, M., Ameri, A., Monjour, A., Nibio, A., Poisson, M., Delattre, J.Y. (1995). Primary central nervous system lymphoma: treatment with chemotherapy and radiotherapy. European Journal of Cancer, 31A, 2003–2007.CrossRefGoogle Scholar
Soussain, C., Suzan, F., Hoang-Xuan, K., et al. (2001). Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Journal of Clinical Oncology, 19, 742–749.CrossRefGoogle Scholar